NASDAQ:MRNA
Moderna (MRNA)
Financials 
Technical Analysis 
Jul 16, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
Moderna (MRNA-Q) has shown remarkable growth, becoming the only non-tech stock in the top 15 of the S&P with a staggering increase of 146% this year. The company has garnered attention for its emerging drugs in clinical trials, particularly in oncology, despite the challenge of not yet turning a profit. Recent approvals of the flu vaccine and the resolution of lawsuits have further fueled investor enthusiasm. There is optimism surrounding personalized anti-cancer vaccines, but this venture is still in the early stages, contributing to the belief that while shares have rallied significantly, a pullback may be warranted. As the biotech landscape is often volatile, many experts remain cautious about long-term participation, suggesting that while the stock performs well currently, risks abound.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentIn past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Premium contentThe stock price has been impacted by news of reduced sales of its COVID19 vaccine. This is to be expected as governments draw down their previously purchased inventory and uptake slows with re-opening. COVID is not going away anytime soon with booster shots expected in the fall. Recently reported earnings beat expectation, showing a gain when analysts expected a loss. The company is also working on a RSV vaccine. It trades at 7x earnings and supports a ROE of 50%. We recommend placing a stop loss at $100, looking to achieve $199 -- upside potential of 45%. Yield 0%
(Analysts’ price target is $198.77)
Premium content
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Down 44% in 2023. They made the first Covid vaccine and made a ton of sales, but they suffer losses now. It didn't pull off a cancer vaccine as some hoped for. But it's up 9% in the past week. Maybe there's hope.